• BM evaluation unlikely to provide specific diagnostic or prognostic information in severe thrombocytopenia
• 36/55 diagnostic BM aspirates had <20x10 3 /µL
• No definitive diagnosis made via BM evaluation
• BM evaluation unlikely to provide specific diagnostic or prognostic information in severe thrombocytopenia
• <24h post-admission, d1 after plt >40, then d4, d7, d14
• All dogs had hypocoagulable TEG tracings on admission
• All dogs developed hypercoagulable TEG tracings
• 24 dogs with primary IMTP
• All Tx with prednisone 1.5-2mg/kg
• 12 dogs treated with vincristine 0.02mg/kg
• Vinc Tx dogs had sig. faster plt recovery times -4.9d ± 1.1 Vs 6.8d ± 4.5
• Vinc Tx sig. reduced duration of hospitalisation -5.4d ± 0.3 Vs 7.3d ± 0.5
• No adverse effects noted
• Prospective RCT of 18 client-owned dogs with IMTP
• Median platelet count recovery time (p=0.018) -hIVIG group 3.5d (2-7) -Placebo group 7.5d (3-12)
• Median hospitalisation (p=0.027) P latelets are anucleate, discoid-shaped, cytoplasmic fragments that play an essential role in primary hemostasis, the initiation of a platelet plug, and the preservation of vascular integrity. Alterations in platelet number as well as platelet function have profound implications for the maintenance of hemostasis and vascular health. Thrombocytopenia, a common finding in critically ill dogs,1,2 is often associated with spontaneous bleeding in dogs3 and in humans.4 Moreover, progressive development of thrombocytopenia has been associated with a poorer outcome in human intensive care unit patients. [5] [6] [7] In human medicine, platelet-rich products are available for the treatment of patients with thrombocytopenia. The most commonly used product is a fresh PC stored at room temperature (20° to 24°C) with continuous, gentle agitation for up to 5 days. Fresh PC can be obtained from whole blood by serial centrifugation or by platelet apheresis. The minimum acceptable platelet count in a PC is 3.0 X 1011 platelets/300-mL bag, as defined by the American Association of Blood Banks.8
Introduction
Hemostasis can be divided into 3 inter-related steps: (1) primary hemostasis, the initiation and formation of a platelet plug, (2) secondary hemostasis, the propagation of thrombin formation for ultimate clot stabilization with cross-linked fibrin, and (3) fibrinolysis, the dissolution of the clot and the restoration of vascular integrity.
Primary hemostasis can be affected by alterations in platelet number as well as platelet function. Thrombocytopenia, a common finding in critically ill dogs,1,2 is often associated with spontaneous bleeding in dogs3 and in humans.4 Moreover, progressive development of thrombocytopenia has been associated with a poorer outcome in critically ill human patients.5-7
Severe thrombocytopenia associated with life-threatening bleeding is usually treated with platelet products. The standard of care in human medicine is the transfusion of platelet concentrate (PC), which is stored for up to 5 days at room temperature (20-241C) with continuous, gentle agitation. PC units can be obtained from whole blood by serial centrifugation or with pheresis technology. The minimum acceptable platelet count in a 
Abstract
Objectives -To describe coagulation abnormalities in dogs following severe acute trauma and to evaluate the relationship between coagulation, clinical, and laboratory variables, and disease and injury severity, as well as the ability of coagulation variables to predict the presence of body cavity hemorrhage (BCH), necessity of blood product administration, and outcome. Design -Prospective, multicenter, observational study. Setting -Two university teaching hospitals. Animals -Forty client-owned dogs sustaining severe blunt or penetrating trauma.
Interventions -Blood samples were collected within 12 hours of the traumatic incident for measurement of blood gases, lactate concentration, platelet count, activated clotting time, prothrombin time, activated partial thromboplastin time (aPTT), fibrinogen concentration, antithrombin activity, D-dimer concentration, protein C activity, plasmin inhibition, plasminogen activity, and kaolin-activated thomboelastography.
Results -Decreased platelet count was a risk factor for the presence of BCH (P = 0.006) and decreased platelet count (P < 0.001), protein C activity (P = 0.001), angle (␣) (P = 0.001), maximum amplitude (MA) (P < 0.001), and clot strength (G) (P = 0.002) were risk factors for blood product administration. Nonsurviving dogs were hypocoagulable with prolonged aPTT (P = 0.008), decreased plasmin inhibition (P = 0.033), decreased ␣ (P = 0.021), and decreased MA (P = 0.038) compared to surviving dogs. Multivariate analysis accounting for disease severity showed that prolonged aPTT (P = 0.004, OR = 1.74) was the strongest predictor of nonsurvival. Prolonged aPTT was positively correlated with APPLE-fast score (P < 0.001, r2 = 0.35), lactate concentration (P < 0.001, r2 = 0.35), and negative base excess (P = 0.001, r2 = 0.27). Acute traumatic coagulopathy, as defined by 2 or more abnormal coagulation tests, was diagnosed in 15% of dogs at hospital admission and was more common in dogs with increased disease severity (P = 0.002), decreased systolic blood pressure (P = 0.002), and increased lactate concentration (P = 0.011).
Conclusions -Indogswithseveretraumaticinjuriesandhypoperfusion,measurementofthromboelastography and aPTT should be considered to support clinical assessments in predicting the need for blood product administration and nonsurvival. Background. ROTEMw/TEGw (rotational thromboelastometry) assays appear to be useful for the treatment of bleeding trauma patients. However, data on the prevalence and impact of abnormal ROTEMw assays are scarce.
Methods. This is a prospective cohort study of blunt trauma patients (Injury Severity Score ≥15 or Glasgow Coma Score ≤14) admitted to Innsbruck Medical University Hospital between July 2005 and July 2008. Standard coagulation tests, antithrombin (AT), prothrombin fragments (F1+2), thrombin-antithrombin complex (TAT), and ROTEMw assays were measured after admission. Data on 334 patients remained for final analysis.
Results. ROTEMw parameters correlated with standard coagulation tests (all Spearman r.0.5), and significant differences in mortality were detected for defined ROTEMw thresholds [FIBTEM 7 mm (21% vs 9%, P¼0.006), EXTEM MCF (maximum clot firmness) 45 mm (25.4% vs 9.4%, P¼0.001)]. EXTEM MCF was independently associated with early mortality [odds ratio (OR) 0.94, 95% confidence interval (CI) 0.9-0.99] and MCF FIBTEM with need for red blood cell transfusion (OR 0.92, 95% CI 0.87-0.98). In polytrauma patients with or without head injury (n¼274), the prevalence of low fibrinogen concentrations, impaired fibrin polymerization, and reduced clot firmness was 26%, 30%, and 22%, respectively, and thus higher than the prolonged international normalized ratio (14%). Hyperfibrinolysis increased fatality rates and occurred as frequently in isolated brain injury (n¼60) as in polytrauma (n¼274) (5%, 95% CI 1.04-13.92 vs 7.3%, 95% CI 4.52-11.05). All patients showed elevated F1+2 and TAT and low AT levels, indicating increased thrombin formation.
Conclusions. Our data enlarge the body of evidence showing that ROTEMw assays are useful in trauma patients. Treatment concepts should focus on maintaining fibrin polymerization and treating hyperfibrinolysis.
Keywords: blood, coagulation; measurement technique, thrombelastograph, thrombelastometry, trauma Accepted for publication: 26 April 2011
Guidelines for managing trauma-induced coagulopathy (TIC) recommend administration of fresh-frozen plasma (FFP) according to measurements of prothrombin time (PT) and activated partial thrombin time, although these tests have never been validated for estimating bleeding tendency or treatment of haemorrhage-induced coagulopathy and cannot reflect quality of clot formation.1 -3 Because strategies for treating the main underlying pathologies of acquired coagulopathy, namely thrombin deficiency, poor clot firmness, and hyperfibrinolysis, are different, knowledge of primary deficiencies is of clinical importance. While thrombin formation has been shown to be sustained in the early phase of severe trauma,45fibrinogen and platelets are consumed by the clot formation process itself. Furthermore, blood loss, dilution, acidosis, and hypothermia, commonly present in injured patients, additionally decrease concentrations of fibrinogen and numbers of platelets.6 Therefore, we hypothesize that on admission, severely injured patients more frequently exhibit low clot firmness and poor fibrin polymerization than impaired thrombin formation. [4] Tranexamic acid almost completely blocks the binding of plasminogen or the heavy chain of plasmin to fibrin, primarily through binding to the high-affinity lysine binding site of plasminogen. Although plasminogen may still be converted to plasmin in the presence of a plasminogen activator, such as tissue plasminogen activator, after binding to tranexamic acid, it can no longer interact with and digest fibrin (figure 2).
British Journal of Anaesthesia
[9] Tranexamic acid also blocks the binding of a2-antiplasmin to plasmin and its inactivation of plasmin.
The binding potency of tranexamic acid to plasminogen is 6-to 10-fold higher than that of the other antifibrinolytic synthetic lysine derivative e-aminocaproic acid in fibrinolytic test systems.
[9] The lysine binding sites in plasminogen reside in separate kringle domains, which are areas of the protein chain characterized by triple loop structures stabilized by three disulfide linkages. Both tranexamic acid and e-aminocaproic acid appear to interact with the low-affinity lysine binding site of the kringle 5 domain. The kringle 5 binding site may mediate the initial association of plasminogen with fibrin. The high-affinity kringle 1 lysine binding site appears to require C-terminal lysine residues that are present on fibrin only after partial digestion of fibrin.
[10] In addition to inhibiting plasmin, tranexamic acid also competitively inhibits the activation of trypsinogen by enterokinase, noncompetitively inhibits trypsin and weakly inhibits thrombin. [9] In contrast, tranexamic acid was shown to dose-dependently increase 
SMALL ANIMALS/ EXOTIC
I n recent years, blood transfusion of veterinary patients has become commonplace. Transfusions may consist of whole blood or blood components, such as packed RBC (PRBC) or fresh-frozen plasma (FFP). Red blood cell transfusions are typically given to correct anemia resulting from hemorrhage, RBC destruction, or inadequate erythropoiesis. Plasma transfusions are indicated to replace coagulation factors and occasionally to treat hypoproteinemia. Retrospective reviews of transfusion practices in veterinary medicine have been published,1-3 and in these reviews, the volume of PRBC given to dogs receiving transfusions was typically 10 to 19 ml/kg (4.5 to 8.6 ml/lb).2,3 Acute blood loss, hemolysis, coagulopathy, and bone marrow failure were the most common indications for transfusion. Survival rates of dogs undergoing transfusion ranged from 47 to 61%,2,3 with most dogs dying of the underlying disease process, rather than an inability to meet blood transfusion requirements.
In human medicine, transfusion of very large amounts of blood is occasionally warranted. Massive transfusion, the term coined for this clinical situation, has been defined as transfusion of a volume of whole blood or blood components that is greater than the patient' s estimated blood volume within a 24-hour period.4-6 Other definitions have included replacement of half the patient' s estimated blood volume in 3 hours,6 administration of blood products at a rate of 1.5 ml/kg/min over a period of 20 minutes, or the replacement of 150% of the patient' s blood volume irrespective of time.5 Given the severity of injuries and disease processes that cause near exsanguination, it should not be surprising that individuals who receive massive transfusion experience numerous complications and a high mortality rate. Some of the reported complications include electrolyte disturbances, coagulation defects, hypothermia, alterations in acid-base status, impaired wound healing, acute lung injury, various transfusion reactions, and transmission of infectious diseases.6-8
Massive transfusion imposes a substantial drain on blood banking resources, with a select few patients consuming a large percentage of a hospital' s blood supply. To date, there have been no reports in the veterinary literature on massive transfusion, and survival rate following this type of blood product expenditure is not known. The purposes of the study reported here were to determine clinical characteristics of dogs that received massive transfusion and identify the underlying diseases, complications, and outcomes associated with massive transfusion in these dogs.
Criteria for Selection of Cases
The Tufts University hospital transfusion log for January 1997 through June 2001 was reviewed, and dogs and cats receiving a substantial volume of blood products relative to body size (approx 1 unit/5 kg [1 unit/11 lb]) were identified. Medical records of these animals were subsequently evaluated to determine whether they met the criteria for massive transfusion. For purposes of this study, massive transfusion was defined as transfusion of a volume of blood products in excess of the patient' s estimated blood volume (90 ml/kg [40 ml/lb] for dogs and 66 ml/kg [30 ml/lb] for cats9) in a 24-hour period or transfusion of a volume of blood products in excess of half the patient' s estimated blood volume in a 3-hour period. Blood products were defined as whole blood, PRBC, or FFP. Blood products were prepared from voluntary donors, stored, and transfused according to standard techniques, as described.10,11 Procedure-Medical records of dogs receiving a massive blood transfusion were evaluated for transfusion volume, underlying disease process or injury, benefits and complications of transfusion, and outcome. A massive transfusion was defined as transfusion of a volume of blood products in excess of the patient's estimated blood volume (90 ml/kg [40 ml/lb]) in a 24-hour period or transfusion of a volume of blood products in excess of half the patient's estimated blood volume in a 3-hour period. Results-Six dogs had intra-abdominal neoplasia resulting in hemoabdomen, 3 had suffered a traumatic incident resulting in hemoabdomen, and 6 had nontraumatic, non-neoplastic blood loss. Mean volumes of packed RBC and fresh-frozen plasma administered were 66.5 ml/kg (30 ml/lb) and 22.2 ml/kg (10 ml/lb), respectively. All dogs evaluated developed low ionized calcium concentrations and thrombocytopenia. Transfusion reactions were recognized in 6 dogs. Four dogs survived to hospital discharge. 
Conclusions and Clinical

Introduction
Transfusion of packed red blood cells (pRBCs) is an increasingly common therapy in small animal veterinary medicine, but one frequently hampered by a lack of availability of blood products. The maintenance of alar gebloodbankr equir esconsiderablemonetaryexpenditure and expertise, and stored blood products may only be available to clinicians in limited quantities.1 The availability of fresh blood products may also be limited, as blood donors should be prescreened to assure good health, ascertain their blood type, and to allow for appropriate infectious disease screening.2 The lack of availability of stored canine pRBCs for transfusion may be partially mitigated by the use of an autologous RBC salvage system or cell saver. Such systems can be used to collect blood from a surgical field or incisional drain. Once collected, viable RBCs may be concentrated and returned to the patient, minimizing the need for stored pRBC transfusion when large volumes of hemorrhage have occurred or are anticipated.3 Cell salvage machines pump the collected blood from a reservoir into a centrifugation bowl where dense RBCs are separated from plasma proteins and lighter cellular elements. The RBCs are then washed and resuspended in 0.9% saline. This blood may then administered to the patient immediately or stored for administration within 6 h of collection.4 Some newer salvage devices utilize a spiral centrifugation system rather than processing batches of blood in a bowl to allow continuous processing of blood and immediate return of salvaged cells to the patient.5 Cell salvage systems are preferable to direct autotransfusion of blood from the surgical field as it removes other contaminants from the collected fluid and allows concentration of pRBCs, minimizing the transfusion volume.
Autotransfusion has traditionally been considered an option of last resort, yet it has potential benefits over traditional allogenic blood transfusion. Autologous blood transfusions ensure RBC antigenic compatibility, maximizing the longevity of transfused cells, minimizing the contribution of a transfusion to inflammation, and removing the costs and delays associated with heparin and in some reports these treatments have led to resolution of the PVT. 122 Even in people, treatment recommendations for PVT are controversial. 127 A recent consensus statement from the American Association for the Study of Liver Diseases recommended that patients with acute PVT (ie, PVT diagnosed in the setting of abdominal pain) receive treatment with anticoagulants (eg, warfarin or heparin) for at least 6 months. 127 These recommendations are based on the observation that 50% of patients will recanalize the portal vein if anticoagulant therapy is initiated promptly, while untreated patients rarely spontaneously recanalize. 186 The indication for treatment of chronic PVT with anticoagulants is less clear, as studies show little benefit in thrombus resolution with treatment. 186, 187 In addition, many human patients with hepatic disease that develop PVT are cirrhotic with preexisting portal hypertension, and the use evaluated in veterinary patients with liver disease and studies are needed in this area. Further studies are also needed to determine with veterinary patients with hepatobiliary disease are at the highest risk for thrombosis and which prophylactic interventions are appropriate.
As a clearer understanding of the role of parenchymal extinction in hepatic disease emerges in the coming years, therapy aimed at hypercoagulability may become a target for slowing the progression of liver disease.
Conclusion
Understanding and evaluating the coagulation status of patients with hepatobiliary disease is a challenge due to the liver's dual role in the synthesis and removal of proand anticoagulant factors. With hepatobiliary disease antagonistic alterations may occur in platelet number Kavanagh C et al. J Vet Emerg Crit Care 2011; 21(6): 589-604 Updates on plasma storage / stability Arterial thromboembolism Equipoise!
• Multi--centre, double--blinded, prospective study
• Cats that experienced a CATE event and survived 1-3 months were eligible for enrollment
• Aspirin (81 mg PO E3d) / Clopidogrel (18.75 mg PO SID)
• 1 o y end--point
• Clinically evident embolic event
• 2 o y end--points
• All--cause mortality, cardiac death, ADR Results: Twenty-six dogs had an apparent primary mural aortic thrombus. None had structural heart disease at diagnosis. Twenty dogs were ambulatory with varying degrees of pelvic limb dysfunction. Duration of ambulatory dysfunction was 7.8 weeks (range 1 daye52 weeks). A majority of dogs (58%) had no concurrent conditions at diagnosis. Fourteen dogs were treated with a standard warfarin protocol for a median period of 22.9 months (range 0.5e53 months). Ambulatory function improved in all dogs treated with warfarin. Time until clinical improvement was 13.9 days (range 2e49 days). Dogs treated with warfarin did not become non-ambulatory, die or undergo euthanasia related to AT, or have a known serious hemorrhagic event.
Conclusions: The pathogenesis of AT in dogs is distinct from that of aortic thromboembolism (ATE) in cats. Aortic thrombosis in dogs is more likely to involve local thrombosis in the distal aorta with embolization to the arteries of the pelvic limb * Previous presentation: This paper was presented in abstract form via oral presentation at the ACVIM Forum in Denver, CO on June 16, 2011.
* Corresponding author. E-mail addresses: rwinter@cvm.tamu.edu, corton@colostate.edu (E.C. Orton). 
SMALL ANIMALS
A ortic thromboembolism occurs commonly in cats and has been addressed extensively in the literature.1-6 Typical clinical signs in feline patients consist of acute-onset hind limb paresis, pain, absent femoral pulses, and nail bed cyanosis.2,3 Although idiopathic cases have been reported,7 most cats have underlying cardiac disease, with congestive heart failure reported in 40% to 66% of cats.2,3,7 Prognosis is typically poor, with a reported rate of survival to discharge of 0% to 50% and 6-month recurrence rate of 45% to 75%.2,8 Low rectal temperature, bradycardia, and multiple limb involvement have all been associated with decreased survival rate.3 Euthanasia is common, occurring in 24% to 35% of cases.3
Clinical information regarding aortic thrombosis in dogs is less thoroughly documented in the current literature. In canine patients, aortic thrombosis has been associated with multiple conditions, including hyperadrenocorticism, protein-losing glomerulonephropathy, infective endocarditis, and neoplasia.9-12 Both acute and chronic onset of disease has been reported,9 and clinical signs include exercise intolerance, hind limb paresis, absent femoral pulses, cold extremities, and signs of pain.9,11,13 Survival rate in dogs with aortic thrombosis Aortic thrombosis in dogs: 31 cases (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) Geri A. Lake-Bakaar, DVM; Eric G. Johnson, DVM, DACVR; Leigh G. Griffiths, VetMB, DACVIM, PhD Objective-To describe clinical signs, treatment, and outcome of aortic thrombosis in dogs. Design-Retrospective case series. Animals-31 dogs with aortic thrombosis. Procedures-Records were retrospectively reviewed and data collected regarding signalment, historical signs, physical examination findings, laboratory testing, definitive diagnosis, and presence of concurrent disease. Results-The records of 31 dogs with clinical or postmortem diagnosis of aortic thrombosis were reviewed. Onset of clinical signs was acute in 14 (45%) dogs, chronic in 15 (48%), and not documented in 2 (6%). Femoral pulses were subjectively weak in 6 (19%) dogs and absent in 17 (55%). Frequent laboratory abnormalities included high BUN concentration (n = 13), creatinine concentration (6), creatine kinase activity (10), and D-dimer concentration (10) and proteinuria with a urine protein-to-creatinine concentration ratio > 0.5 (12). Concurrent conditions included neoplasia (n = 6), recent administration of corticosteroids (6), and renal (8) or cardiac (6) disease. Median survival time was significantly longer for dogs with chronic onset of disease (30 days; range, 0 to 959 days) than for those with acute onset of clinical signs (1.5 days; range, 0 to 120 days). Conclusions and Clinical Relevance-Results suggested that aortic thrombosis is a rare condition in dogs and accounted for only 0.0005% of hospital admissions during the study period. The clinical signs for dogs with aortic thrombosis differed from those seen in feline patients with aortic thromboembolism. Median survival time was significantly longer for dogs with chronic disease than for dogs with acute disease. Despite treatment, outcomes were typically poor, although protracted periods of survival were achieved in some dogs. (J Am Vet Med Assoc 2012; 241:910-915) has been reported to exceed that of cats with ATE; however, the prognosis and rate of recurrence have not been fully addressed.9,13
In feline patients, the outcome of therapeutic interventions, including thrombolytic treatment with streptokinase or t-PA or long-term anticoagulant treatment with acetylsalicylic acid, clopidogrel, warfarin, and heparin, has been reported. 1, 5, 6, 8, 14 The literature concerning therapeutic intervention in dogs is sparse and conflicting.9 Two case reports14,15 of dogs reported streptokinase or t-PA administration to result in partial or complete thrombus resolution. However, another case report9 indicated that t-PA treatment was ineffective. To our knowledge, there are no reports of long-term management of the disease.
The purpose of the study reported here was to describe the clinical signs and diagnostic findings for dogs with aortic thrombosis and assess associations with survival data. We also aimed to describe short-term (thrombolytic drug treatment and rheolytic thrombectomy) and long-term (anticoagulant and antiplatelet treatment) therapeutic interventions. Identifying risk factors
INTRODUCTION
Pulmonary thromboembolism (PTE) is the obstruction of the pulmonary artery or its branches by thrombi and is a major cause of morbidity and mortality in dogs with immune-mediated haemolytic anaemia (IMHA) (Reimer et al. 1999 , Scott-Moncrieff et al. 2001 . Dogs with IMHA are predisposed to PTE potentially because of an associated hypercoagulable state (Fenty et al. 2011 , Goggs et al. 2012 ) that may result from increased intravascular tissue factor expression secondary to the marked inflammatory response that accompanies the disease (Piek et al. 2011 , Kidd & Mackman 2013 . There is also evidence of platelet activation in
